Renee Heffron1, R Scott McClelland2, Jennifer E Balkus3, Connie Celum2, Craig R Cohen4, Nelly Mugo5, Elizabeth Bukusi6, Deborah Donnell7, Jairam Lingappa8, James Kiarie9, Tina Fiedler10, Matthew Munch10, David N Fredricks10, Jared M Baeten2. 1. Department of Global Health, University of Washington, Seattle, WA, USA; Department of Epidemiology, University of Washington, Seattle, WA, USA. Electronic address: rheffron@uw.edu. 2. Department of Global Health, University of Washington, Seattle, WA, USA; Department of Epidemiology, University of Washington, Seattle, WA, USA; Department of Medicine, University of Washington, Seattle, WA, USA. 3. Department of Epidemiology, University of Washington, Seattle, WA, USA; Vaccine and Infectious Disease Division, Fred Hutch, Seattle, WA, USA. 4. Department of Obstetrics, Gynecology, and Reproductive Sciences, University of California, San Francisco, San Francisco, CA, USA. 5. Department of Global Health, University of Washington, Seattle, WA, USA; Centre for Clinical Research, Nairobi, Kenya; Kenya Medical Research Institute, Nairobi, Kenya. 6. Department of Global Health, University of Washington, Seattle, WA, USA; Department of Obstetrics and Gynecology, University of Washington, Seattle, WA, USA; Centre for Microbiology Research, Nairobi, Kenya. 7. Department of Global Health, University of Washington, Seattle, WA, USA; Vaccine and Infectious Disease Division, Fred Hutch, Seattle, WA, USA. 8. Department of Global Health, University of Washington, Seattle, WA, USA; Department of Medicine, University of Washington, Seattle, WA, USA; Department of Pediatrics, University of Washington, Seattle, WA, USA. 9. Human Reproduction Programme, WHO, Geneva, Switzerland. 10. Vaccine and Infectious Disease Division, Fred Hutch, Seattle, WA, USA.
Abstract
BACKGROUND: Daily oral tenofovir-based pre-exposure prophylaxis (PrEP) is high efficacious for HIV prevention among women with high adherence. However, the effect of abnormal vaginal microbiota on PrEP efficacy is of concern. We investigated whether bacterial vaginosis modified the efficacy of oral PrEP. METHODS: We used prospectively collected data from women in the Partners PrEP Study, a placebo-controlled trial of daily oral PrEP (either tenofovir monotherapy or a combination of tenofovir and emtricitabine) in HIV serodiscordant couples aged 18 years or older in Kenya and Uganda that showed high efficacy in women. We used Cox proportional hazards regression to assess PrEP efficacy among subgroups of women defined by bacterial vaginosis status based on yearly microscopy and Nugent scoring (0-3 indicated healthy microbiota, 4-6 intermediate, and 7-10 bacterial vaginosis). In separate efficacy analyses, we also investigated individual components of the score (ie, detection of Gardnerella vaginalis or Bacteroides spp and non-detection of Lactobacillus spp) as markers of abnormal microbiota. FINDINGS: Of 1470 women (median age 33 years), 357 (24%) had bacterial vaginosis at enrolment. 45 women seroconverted to HIV. The HIV prevention efficacy of PrEP did not differ significantly among women with healthy microbiota (incidence 0·6 per 100 person years in PrEP group and 2·5 per 100 person-years in the placebo group; efficacy 76·55% [95% CI 43·09 to 90·37]), intermediate microbiota (HIV incidence 1·8 per 100 person-years in the PrEP group and 3·5 per 100 person-years in the placebo group; efficacy 62·72% [95% CI -66·59 to 91·66]), or bacterial vaginosis (HIV incidence 0·9 per 100 person-years in the PrEP group and 3·5 per 100 person-years in the placebo group; efficacy 72·50% [95% CI 5·98 to 91·95]; pinteraction=0·871). PrEP efficacy was not significantly different between women with detected G vaginalis or Bacteroides spp morphotypes and those without these morphotypes (efficacy 68·62% vs 76·72%; pinteraction=0·652); or between those with Lactobacillus spp morphotypes and those without (70·48% vs 74·08%; pinteraction=0·86). INTERPRETATION: Among African women with a high prevalence of bacterial vaginosis and high adherence to PrEP, the efficacy of daily oral PrEP for HIV prevention did not differ significantly among women with abnormal versus healthy vaginal microbiota as defined by Nugent score. These data are reassuring that oral PrEP delivery to women can continue without the need for concurrent testing for bacterial vaginosis or vaginal dysbiosis. FUNDING: Bill & Melinda Gates Foundation, Eunice Kennedy Shriver National Institute of Child Health and Human Development, and National Institute of Allergy and Infectious Diseases.
BACKGROUND: Daily oral tenofovir-based pre-exposure prophylaxis (PrEP) is high efficacious for HIV prevention among women with high adherence. However, the effect of abnormal vaginal microbiota on PrEP efficacy is of concern. We investigated whether bacterial vaginosis modified the efficacy of oral PrEP. METHODS: We used prospectively collected data from women in the Partners PrEP Study, a placebo-controlled trial of daily oral PrEP (either tenofovir monotherapy or a combination of tenofovir and emtricitabine) in HIV serodiscordant couples aged 18 years or older in Kenya and Uganda that showed high efficacy in women. We used Cox proportional hazards regression to assess PrEP efficacy among subgroups of women defined by bacterial vaginosis status based on yearly microscopy and Nugent scoring (0-3 indicated healthy microbiota, 4-6 intermediate, and 7-10 bacterial vaginosis). In separate efficacy analyses, we also investigated individual components of the score (ie, detection of Gardnerella vaginalis or Bacteroides spp and non-detection of Lactobacillus spp) as markers of abnormal microbiota. FINDINGS: Of 1470 women (median age 33 years), 357 (24%) had bacterial vaginosis at enrolment. 45 women seroconverted to HIV. The HIV prevention efficacy of PrEP did not differ significantly among women with healthy microbiota (incidence 0·6 per 100 person years in PrEP group and 2·5 per 100 person-years in the placebo group; efficacy 76·55% [95% CI 43·09 to 90·37]), intermediate microbiota (HIV incidence 1·8 per 100 person-years in the PrEP group and 3·5 per 100 person-years in the placebo group; efficacy 62·72% [95% CI -66·59 to 91·66]), or bacterial vaginosis (HIV incidence 0·9 per 100 person-years in the PrEP group and 3·5 per 100 person-years in the placebo group; efficacy 72·50% [95% CI 5·98 to 91·95]; pinteraction=0·871). PrEP efficacy was not significantly different between women with detected G vaginalis or Bacteroides spp morphotypes and those without these morphotypes (efficacy 68·62% vs 76·72%; pinteraction=0·652); or between those with Lactobacillus spp morphotypes and those without (70·48% vs 74·08%; pinteraction=0·86). INTERPRETATION: Among African women with a high prevalence of bacterial vaginosis and high adherence to PrEP, the efficacy of daily oral PrEP for HIV prevention did not differ significantly among women with abnormal versus healthy vaginal microbiota as defined by Nugent score. These data are reassuring that oral PrEP delivery to women can continue without the need for concurrent testing for bacterial vaginosis or vaginal dysbiosis. FUNDING: Bill & Melinda Gates Foundation, Eunice Kennedy Shriver National Institute of Child Health and Human Development, and National Institute of Allergy and Infectious Diseases.
Authors: Quarraisha Abdool Karim; Salim S Abdool Karim; Janet A Frohlich; Anneke C Grobler; Cheryl Baxter; Leila E Mansoor; Ayesha B M Kharsany; Sengeziwe Sibeko; Koleka P Mlisana; Zaheen Omar; Tanuja N Gengiah; Silvia Maarschalk; Natasha Arulappan; Mukelisiwe Mlotshwa; Lynn Morris; Douglas Taylor Journal: Science Date: 2010-07-19 Impact factor: 47.728
Authors: Christina Gosmann; Melis N Anahtar; Scott A Handley; Mara Farcasanu; Galeb Abu-Ali; Brittany A Bowman; Nikita Padavattan; Chandni Desai; Lindsay Droit; Amber Moodley; Mary Dong; Yuezhou Chen; Nasreen Ismail; Thumbi Ndung'u; Musie S Ghebremichael; Duane R Wesemann; Caroline Mitchell; Krista L Dong; Curtis Huttenhower; Bruce D Walker; Herbert W Virgin; Douglas S Kwon Journal: Immunity Date: 2017-01-10 Impact factor: 31.745
Authors: Mackenzie L Cottrell; Kuo H Yang; Heather M A Prince; Craig Sykes; Nicole White; Stephanie Malone; Evan S Dellon; Ryan D Madanick; Nicholas J Shaheen; Michael G Hudgens; Jacob Wulff; Kristine B Patterson; Julie A E Nelson; Angela D M Kashuba Journal: J Infect Dis Date: 2016-02-24 Impact factor: 5.226
Authors: Melis N Anahtar; Elizabeth H Byrne; Kathleen E Doherty; Brittany A Bowman; Hidemi S Yamamoto; Magali Soumillon; Nikita Padavattan; Nasreen Ismail; Amber Moodley; Mary E Sabatini; Musie S Ghebremichael; Chad Nusbaum; Curtis Huttenhower; Herbert W Virgin; Thumbi Ndung'u; Krista L Dong; Bruce D Walker; Raina N Fichorova; Douglas S Kwon Journal: Immunity Date: 2015-05-19 Impact factor: 31.745
Authors: Jared M Baeten; Deborah Donnell; Patrick Ndase; Nelly R Mugo; James D Campbell; Jonathan Wangisi; Jordan W Tappero; Elizabeth A Bukusi; Craig R Cohen; Elly Katabira; Allan Ronald; Elioda Tumwesigye; Edwin Were; Kenneth H Fife; James Kiarie; Carey Farquhar; Grace John-Stewart; Aloysious Kakia; Josephine Odoyo; Akasiima Mucunguzi; Edith Nakku-Joloba; Rogers Twesigye; Kenneth Ngure; Cosmas Apaka; Harrison Tamooh; Fridah Gabona; Andrew Mujugira; Dana Panteleeff; Katherine K Thomas; Lara Kidoguchi; Meighan Krows; Jennifer Revall; Susan Morrison; Harald Haugen; Mira Emmanuel-Ogier; Lisa Ondrejcek; Robert W Coombs; Lisa Frenkel; Craig Hendrix; Namandjé N Bumpus; David Bangsberg; Jessica E Haberer; Wendy S Stevens; Jairam R Lingappa; Connie Celum Journal: N Engl J Med Date: 2012-07-11 Impact factor: 91.245
Authors: Kenneth H Mayer; Lisa A Maslankowski; Fang Gai; Wafaa M El-Sadr; Jessica Justman; Antonia Kwiecien; Benoît Mâsse; Susan H Eshleman; Craig Hendrix; Kathleen Morrow; James F Rooney; Lydia Soto-Torres Journal: AIDS Date: 2006-02-28 Impact factor: 4.177
Authors: Nicola Low; Matthew F Chersich; Kurt Schmidlin; Matthias Egger; Suzanna C Francis; Janneke H H M van de Wijgert; Richard J Hayes; Jared M Baeten; Joelle Brown; Sinead Delany-Moretlwe; Rupert Kaul; Nuala McGrath; Charles Morrison; Landon Myer; Marleen Temmerman; Ariane van der Straten; Deborah Watson-Jones; Marcel Zwahlen; Adriane Martin Hilber Journal: PLoS Med Date: 2011-02-15 Impact factor: 11.069
Authors: Cindy M Liu; Zoe R Packman; Alison G Abraham; David M Serwadda; Fred Nalugoda; Maliha Aziz; Jessica L Prodger; Rupert Kaul; Sarah Kalibbala; Ronald H Gray; Lance B Price; Thomas C Quinn; Aaron Ar Tobian; Steven J Reynolds Journal: Open Forum Infect Dis Date: 2019-07-12 Impact factor: 3.835
Authors: Minlu Hu; Guru R Valicherla; Tian Zhou; Sharon L Hillier; Lisa C Rohan Journal: AIDS Res Hum Retroviruses Date: 2021-03-09 Impact factor: 2.205